[ad_1]
At the beginning of 2020, novo nordisk (NYSE:NVO) It was worth about $150 billion. Currently, the company’s market capitalization exceeds $500 billion, making it one of the most valuable healthcare companies in the world.
A big part of the reason is the growing popularity of two drugs: Ozempic and Wegovy. Both are associated with helping patients lose significant weight. Thanks to social media, demand for this treatment has exploded and stock prices have reached new heights.
But how dependent is Novo Nordisk on these two drugs? And does it pose a risk to investors?
Obesity care sales were behind strong fourth quarter numbers
In the last three months of 2023, Novo Nordisk achieved 37% year-on-year revenue growth, with net sales totaling 65.9 billion Danish kroner ($9.9 billion).
One big reason is that bariatric care sales increased by 105%. What’s important to note for investors is that obesity care includes Wegovy and Saxenda; not included Ozempic is a drug used off-label by diabetics as a treatment for weight loss.
Ozempic and Wigovy as a percentage of Novo Nordisk’s sales
Wegovy is still in its early stages of growth, with sales of DKK 9.6 billion ($1.4 billion) last quarter, compared to Ozempic’s sales of just over DKK 30 billion ($4.5 billion). Together these accounted for his 60% of the company’s total revenue.
The company also has an oral version of Ozempic called Rybelsus. And when you include that revenue ($886 million), nearly 70% of his revenue comes from just three of his products. The company is still working on a verbal version of his Wegovy, which, if approved, could become another huge revenue-generating product for the business.
For some investors, the company may not be diverse enough to be a safe long-term investment. But at the same time, focusing on high-need areas such as diabetes and obesity where there is significant long-term potential can help companies focus their efforts, increase efficiency, and improve overall outcomes. .
Is Novo Nordisk a good stock to buy?
There is no doubt that Novo Nordisk relies on Ozempic and Wigoby. And in the future, we may become even more dependent on oral weight loss drugs. But every healthcare company has one or two key products that are critical to long-term success. For growth-minded investors, the lack of a more diversified growth product shouldn’t deter you from buying Novo Nordisk stock.
This is a powerhouse company that has been developing diabetes and weight loss products for many years. The company is well-positioned to meet the growing needs of these areas of healthcare in the future, which makes it a great stock to have in your portfolio today.
Should you invest $1,000 in Novo Nordisk right now?
Before buying Novo Nordisk stock, consider the following:
of Motley Fool Stock Advisor Our analyst team has identified what they believe Best 10 stocks What investors can buy right now…and Novo Nordisk wasn’t among them. These 10 stocks have the potential to generate impressive returns over the next few years.
stock advisor provides investors with an easy-to-understand blueprint for success, including guidance on portfolio construction, regular updates from analysts, and two new stocks each month.of stock advisor Since 2002, the service has more than tripled S&P 500 returns*.
See 10 stocks
*Stock Advisor returns as of February 6, 2024
David Jagielski has no position in any stocks mentioned. The Motley Fool recommends Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Source link
